Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
In: Annals of Oncology, Jg. 32 (2021-02-01), Heft 2, S. 197-207
Online
academicJournal
Zugriff:
Titel: |
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
|
---|---|
Autor/in / Beteiligte Person: | Dent, S. ; Cortés, J. ; Im, Y. H. ; Diéras, V. ; Harbeck, N. ; Krop, I.E. ; Wilson, T.R. ; Cui, N. ; Schimmoller, F. ; Hsu, J.Y. ; He, J. ; De Laurentiis, M. ; Sousa, S. ; Drullinsky, P. ; Jacot, W. |
Link: | |
Zeitschrift: | Annals of Oncology, Jg. 32 (2021-02-01), Heft 2, S. 197-207 |
Veröffentlichung: | 2021 |
Medientyp: | academicJournal |
ISSN: | 0923-7534 (electronic) |
DOI: | 10.1016/j.annonc.2020.10.596 |
Sonstiges: |
|